Aggregated price index with volume information
- The momentum of the sector is very strong.
- Gene Therapy stocks up 0.3% on average while median return up -0.6% in a day
- Gene Therapy stocks up 6.5% on average while median return up 6.7% in a week
- Gene Therapy stocks up 20.4% on average while median return up 13.0% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $CRSP 38.5%, $EDIT 32.1%, $SLDB 32.0%, $RGNX 28.0%, $BLUE 24.4%
- 1M losers are : Losers for past month are $MGTX -4.2%, $ADVM -5.0%, $AVRO -12.7%
- 1W winners are : Winners for past week are $SLDB 33.0%, $RCKT 12.9%, $BLUE 12.8%, $CAPR 11.5%, $AVRO 11.3%
- 1W losers are : Losers for past week are $CRSP -0.1%, $NTLA -2.8%, $QURE -3.6%, $MGTX -5.9%
Index correlation analysis
Correlation for the past month is 29.1%, for the past 3 months is 22.6%
In the past month for a 5 days rolling window, the highest corrrelation is 49.3%, the lowest correlation is 1.3%, the latest correlation is 23.2%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 88.5% between EDIT and NTLA
The lowest correlation is -32.2% between ADVM and VYGR
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
In this article, we discuss billionaire Louis Bacon’s 10 stock picks with huge upside potential. To skip the details about Mr. Bacon’s life, portfolio performance, and investment strategy, go directly to Billionaire Louis Bacon’s 5 Stock Picks with Huge Upside Potential. Louis Bacon is a macro-trading legend on Wall Street. Macro traders capitalize on financial […]
Biotechs specializing in gene editing are making serious strides, but many are still clinical-stage companies. Editas Medicine's pipeline is pretty thin, but the company does have one key candidate called EDIT-301. One reason behind Editas' strong stock market performance this year is that it recorded positive data from an ongoing phase 1/2 clinical trial for EDIT-301 in five patients, including four with SCD and just one with TDT.
Now is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. You'll find a lot of these candidates in the area of biotech, and two possibilities that come to mind right now are gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) and genetic-testing specialist Invitae (NYSE: NVTA). Which is the better growth stock to buy now?
The gene editing biotech is shelving two of its most advanced cancer drugs, and joining a growing group of companies exploring cell-based medicines for inflammatory diseases like lupus.
We've also got a look at two stocks worth watching and the popular toys for this holiday season.
-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70- -Expanding trials of CTX112 into autoimmune disease, with planned initiation in the first half of 2024, in addition to the ongoing clinical trial in B-cell malignancies- -Expanding trials of CTX131 into hematologic malignancies, including T- and B-cell malignancies, in addition to the ongoing clinical trial in solid tumors- -Next-genera
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
CRISPR Therapeutics' (NASDAQ: CRSP) stock has soared this year -- and for good reason. The biotech company is getting closer and closer to a major milestone: potential regulatory approval of what may become its first product. In just a few days, the U.S. Food and Drug Administration (FDA) will decide on exa-cel for sickle cell disease -- and in March, the agency will consider exa-cel for beta thalassemia.
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.